LOGIN  |  REGISTER
Terns Pharmaceuticals

Neumora Therapeutics to Participate in Upcoming Conferences in November

October 30, 2023 | Last Trade: US$10.63 0.49 -4.41

WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November:

  • Guggenheim Healthcare Talks 5th Annual INI Conference: Members of management will participate in a fireside chat on Monday, November 6, 2023, at 1:50 PM ET in New York, NY.

  • Stifel 2023 Healthcare Conference: Members of management will participate in a fireside chat on Wednesday, November 15, 2023, at 11:30 AM ET in New York, NY.

A live webcast of each event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcasts will be available following the completion of the events and will be archived for up to 30 days.

About Neumora

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Neumora’s therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora’s work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases. For additional information, please visit www.neumoratx.com and follow on Twitter: @NeumoraTx.

Neumora Contact
Helen Rubinstein
This email address is being protected from spambots. You need JavaScript enabled to view it. 
315-382-3979

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB